...
首页> 外文期刊>Journal of clinical densitometry >Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
【24h】

Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.

机译:接受(131)I对更年期状态影响的前甲状腺功能亢进妇女长期甲状腺功能亢进后的骨量。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to assess bone mineral density (BMD) and bone markers in former hyperthyroid females after long-term euthyroidism (>4 yr) following (131)I therapy, as well as the potential influence of the timing of menopause. Twenty-six females ages 57 +/- 8 yr previously diagnosed with hyperthyroidism and treated with (131)I who were euthyroid for a minimum of the last 4 yr (10 +/- 5 yr) were studied. Eighteen patients (69%) were on levothyroxine (LT(4)) replacement therapy for 9 +/- 4 yr. BMD (g/cm(2) and Z-score) was measured by dual X-ray absorptiometry in the lumbar spine, femoral neck, and Ward's triangle. BMD (Z-score) was lower than the normal reference values for the Spanish population in all sites (lumbar spine: -0.65 +/- 1.13; femoral neck: -0.47 +/- 0.95; Ward's triangle: -0.37 +/- 0.88). No differences were found between BMD values according to the etiology of the hyperthyroidism or current LT(4) therapy. Current postmenopausal patients (n = 21) showed lower BMD than current premenopausal patients in the lumbar spine and femoral neck (p < 0.05). Those women who were postmenopausal at the time of the (131)I therapy (n = 15) also had lower lumbar spine BMD than premenopausal patients (p = 0.01), while no significant difference in BMD was seen according to the menopausal status when hyperthyroidism was diagnosed. Former hyperthyroid patients after long-term euthyroidism following (131)I therapy showed reduced BMD at the lumbar spine and proximal femur. Menopausal women showed a greater reduction in bone density. The menopausal status at the time of diagnosis did not seem to have long-term effects in bone density; nevertheless, an early therapeutic intervention in premenopause is suggested to reduce bone loss.
机译:这项研究的目的是评估(131)I治疗后长期甲状腺功能亢进(> 4年)后的前甲状腺功能亢进女性的骨矿物质密度(BMD)和骨标志物,以及更年期的潜在影响。研究了26名女性,年龄57 +/- 8岁,先前被诊断患有甲状腺功能亢进并接受(131)I治疗,这些患者在最近4年(10 +/- 5岁)中至少接受了甲状腺功能正常。 18例患者(69%)接受左甲状腺素(LT(4))替代治疗9 +/- 4年。 BMD(g / cm(2)和Z评分)通过腰椎,股骨颈和Ward三角区的双X线吸收法测量。在所有部位,BMD(Z评分)均低于西班牙人群的正常参考值(腰椎:-0.65 +/- 1.13;股骨颈:-0.47 +/- 0.95;沃德三角形:-0.37 +/- 0.88 )。根据甲亢的病因或当前的LT(4)治疗,BMD值之间未发现差异。目前绝经后患者(n = 21)的腰椎和股骨颈骨密度低于目前绝经前患者(p <0.05)。在(131)I治疗时绝经后的妇女(n = 15)也比绝经前患者的腰椎BMD低(p = 0.01),而根据甲亢时的绝经状态,BMD没有显着差异。被诊断出。前(131)I治疗后长期甲状腺功能亢进的甲状腺功能亢进患者显示腰椎和股骨近端BMD降低。绝经妇女的骨密度降低更大。诊断时的绝经状态似乎对骨密度没有长期影响;但是,建议对绝经前进行早期治疗以减少骨质流失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号